ReviewInternational journal of molecular sciences2026
Autophagy in Ovarian Cancer, an Opportunity or an Additional Threat?
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite extensive research, the treatment of ovarian cancer remains a significant challenge. One promising strategy involves the regulation of autophagy in cancer cells. However, this process is exceptionally complex and, depending on numerous factors, it can either suppress tumor progression, by maintaining genomic stability and limiting inflammatory responses, or exert a pro-tumor effect, enabling cancer cells to survive in unfavorable environmental conditions. Furthermore, the activation of this pathway can contribute to the development of resistance to drugs used in ovarian cancer therapy, such as cisplatin or paclitaxel. Current therapeutic approaches focus on both the induction and inhibition of autophagy, primarily by targeting the two most important pathways regulating this process: PI3K/Akt/mTOR and AMPK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.